JAPAN, June 24, 2026
REPROCELL Inc. announced the submission of a manufacturing and marketing approval application in Japan for Stemchymal®, a regenerative medicine product intended to suppress the progression of spinocerebellar ataxia (SCA3 and SCA6). The application marks a significant regulatory milestone for the stem cell therapy, for which REPROCELL holds exclusive commercialization rights in Japan. Spinocerebellar ataxia is a progressive and debilitating neurodegenerative disorder characterized by worsening loss of coordination, balance, and motor function. With limited treatment options currently available, patients face substantial unmet medical needs. REPROCELL believes Stemchymal® could offer a novel therapeutic approach aimed at slowing disease progression and improving quality of life for individuals affected by these rare inherited neurological conditions.
Orphan Regenerative Medicine Designation Supports Accelerated Review
Stemchymal® previously received Orphan Regenerative Medicine Product designation from Japan’s Ministry of Health, Labour and Welfare (MHLW) in December 2018. The designation is granted to regenerative medicine products targeting rare diseases affecting fewer than 50,000 patients in Japan and addressing significant unmet medical needs. As a result of this status, Stemchymal® qualifies for priority regulatory support, including expedited consultations and an accelerated review process. Under Japan’s regulatory framework, the product is eligible for Priority Review, which targets a review period of approximately nine months following application acceptance. The designation highlights both the rarity of spinocerebellar ataxia and the urgent need for innovative treatment options capable of addressing disease progression where effective therapies remain limited.
REPROCELL and Steminent Partner to Bring Therapy to Patients
Under the commercialization arrangement, Steminent Biotherapeutics Inc., based in Taiwan, will be responsible for manufacturing Stemchymal®, while REPROCELL will oversee sales, marketing, and distribution activities throughout Japan. The collaboration combines Steminent’s expertise in regenerative medicine development with REPROCELL’s capabilities in bringing advanced cell-based therapies to the Japanese healthcare market. Company leadership emphasized that the approval submission represents an important step toward making a potentially transformative treatment available to patients suffering from progressive neurological decline. If approved, Stemchymal® could become one of the few regenerative medicine therapies available for spinocerebellar ataxia, reinforcing Japan’s position as a global leader in the advancement and commercialization of innovative cell therapies.
Advertisement
Regenerative Medicine Continues Expanding in Rare Disease Treatment
According to REPROCELL Chief Executive Officer Chikafumi Yokoyama, the company remains committed to advancing Stemchymal® through the regulatory process and delivering the therapy to patients as quickly as possible. While the company expects minimal short-term financial impact from the submission during the fiscal year ending March 2027, management views the application as a strategically important milestone that could support long-term growth and value creation. The filing also reflects the growing momentum of regenerative medicine in addressing rare and difficult-to-treat diseases. As regulatory agencies increasingly support innovative cell therapies through accelerated review pathways, products such as Stemchymal® may play a critical role in expanding treatment options for patients with severe neurological disorders while advancing the broader field of regenerative and precision medicine.
Source: REPROCELL press release
